{"id":744,"date":"2021-01-02T06:10:37","date_gmt":"2021-01-02T06:10:37","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=744"},"modified":"2021-01-02T06:11:54","modified_gmt":"2021-01-02T06:11:54","slug":"29-dec-2020-nitazoxanide-early-nitazoxanide-therapy-was-safe-and-reduced-viral-load-significantly","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/29-dec-2020-nitazoxanide-early-nitazoxanide-therapy-was-safe-and-reduced-viral-load-significantly\/","title":{"rendered":"(29 Dec 2020) Nitazoxanide- early nitazoxanide therapy was safe and reduced viral load significantly"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial<\/p>\n<p><a href=\"https:\/\/doi.org\/10.1183\/13993003.03725-2020\">https:\/\/doi.org\/10.1183\/13993003.03725-2020<\/a><\/p>\n<p class=\"\">NCT04552483- In a multicenter, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and\/or fatigue) were enrolled. After confirmation of SARS-CoV2 infection by RT-PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, TID, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biomarkers of inflammation, and hospitalisation rate. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm (p=0.009). Viral load was also reduced after nitazoxanide compared to placebo (p=0.006). The percent viral load reduction from onset to end of therapy was higher with nitazoxanide (55%) than placebo (45%) (p=0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed.In patients with mild Covid-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial https:\/\/doi.org\/10.1183\/13993003.03725-2020 NCT04552483- In a multicenter, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and\/or fatigue) were enrolled. After&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/29-dec-2020-nitazoxanide-early-nitazoxanide-therapy-was-safe-and-reduced-viral-load-significantly\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(29 Dec 2020) Nitazoxanide- early nitazoxanide therapy was safe and reduced viral load significantly&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,85],"tags":[86],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/744"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=744"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/744\/revisions"}],"predecessor-version":[{"id":745,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/744\/revisions\/745"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}